Remove Biopharma Remove Contract research organization Remove Ecosystems
article thumbnail

Are You Leveraging the Drug Discovery and Early Development Outsourcing Services Ecosystem to Accelerate Growth?

Frost & Sullivan

However, the pharma/biopharma industry shows overall stagnant R&D activity. Small-to-mid and emerging biopharma players contribute over 16%. Growing demand for outsourcing, with contract research organizations (CROs) and contract development and manufacturing organizations (CDMOs) leading industry growth.

article thumbnail

Pharmaceutical Outsourcing Evolution: The Rise of Clinical Peripheral Services

Frost & Sullivan

The Expanding Role of Clinical Contract Peripheral Services As the pharmaceutical and biopharma industries recalibrate after the COVID-19 pandemic, clinical trial outsourcing has surged, creating significant opportunities for contract research organizations (CROs). The global CRO industry, valued at $66.39